Equities

JW (Cayman) Therapeutics Co Ltd

JW (Cayman) Therapeutics Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.37
  • Today's Change0.13 / 10.48%
  • Shares traded1.13m
  • 1 Year change-31.84%
  • Beta1.8321
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

JW (Cayman) Therapeutics Co Ltd is a company primarily engaged in research and development, manufacturing, and marketing of cellular immunotherapy products. The Company has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. The Company’s main product, Carteyva, is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) cell immunotherapy product independently developed by the Company based on a CAR-T cell process platform of Juno (a Bristol Myers Squibb company). The Company mainly conducts its business in the domestic market.

  • Revenue in HKD (TTM)190.31m
  • Net income in HKD-690.94m
  • Incorporated2017
  • Employees323.00
  • Location
    JW (Cayman) Therapeutics Co LtdNo 225 Meisheng RoadPilot Free Trade Zone, 4f, Building 42SHANGHAI KY1-1104ChinaCHN
  • Websitehttps://www.jwtherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sirnaomics Ltd0.00-637.43m280.44m90.00--147.49-----8.39-8.390.000.02170.00----0.00-110.32---136.58-------------3.25--------10.88------
Clover Biopharmaceuticals Ltd31.80m-973.15m282.76m323.00------8.89-0.7803-0.78030.0255-0.70660.01190.01498.8082,175.72-36.27---405.86--54.86---3,060.03--0.4426----------94.35------
Antengene Corp Ltd61.70m-582.73m364.44m178.00--0.3333--5.91-0.9448-0.94480.101.620.0350.65971.57306,976.90-33.06-53.57-37.16-58.9484.84---944.43-1,987.015.66-23.740.1663---57.97--3.38--202.03--
Kintor Pharmaceutical Ltd0.00-1.01bn420.65m175.00--0.9762-----2.36-2.360.000.9630.000.1411--0.00-70.41-50.15-87.57-58.43---27.62---10,511.411.56-111.480.3788-------11.15---32.49--
HighTide Therapeutics Inc0.00-660.85m437.56m66.00--0.6656-----1.42-1.420.001.280.00----0.00-87.01---118.34--------------0.0404-------393.76------
JW (Cayman) Therapeutics Co Ltd190.31m-690.94m514.81m323.00--0.3136--2.71-1.68-1.680.46143.950.07471.8711.48478,163.50-27.11-39.77-31.71-44.0050.40---363.06-1,316.812.76--0.2043--19.32--9.23---19.87--
Brii Biosciences Ltd0.00-292.12m679.38m95.00--0.2157-----0.4003-0.40030.004.310.00----0.00-8.89---9.01--------------0.007---98.80--63.90------
Genor Biopharma Holdings Ltd15.92m-578.31m857.97m28.00--0.7257--53.88-1.14-1.140.03132.270.00930.01780.2277153,116.50-33.87-55.46-39.06-63.7397.5966.56-3,638.27-14,819.185.73--0.003---100.00--7.65---48.85--
Sunho Biologics Inc-100.00bn-118.07m924.33m----1.53-----0.8765-0.8765--3.85------------------------14.77-4,626.670.0516-------155.25------
Wuhan YZY Biopharma Co Ltd0.00-201.97m1.20bn114.00--21.92-----1.06-1.060.000.28150.00----0.00-83.99---230.17----------1.21-44.350.7078-------1.50------
Frontage Holdings Corp2.03bn47.53m1.24bn1.66k26.530.47353.670.6130.0230.0230.98921.290.470156.234.181,151,748.001.064.461.305.2828.5634.002.269.921.252.190.3110.003.7925.61-58.00-0.782640.43--
Hua Medicine119.89m-289.85m1.26bn172.00------10.48-0.2957-0.29570.1223-0.03720.07791.511.90677,343.20-18.84-25.61-23.63-28.8137.72---241.76-1,654.704.64--1.14--335.31---3.80--14.07--
Mabpharm Ltd166.86m-227.72m1.26bn347.00--9.92--7.54-0.0552-0.05520.04050.03070.1640.19373.26480,867.20-22.38-21.42-31.11-27.4986.91---136.47-486.400.6836-23.090.679--55.87--0.694---26.85--
Data as of Sep 20 2024. Currency figures normalised to JW (Cayman) Therapeutics Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.81%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 31 May 20241.44m0.35%
Norges Bank Investment Managementas of 31 Dec 2023917.99k0.22%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023300.00k0.07%
China Universal Asset Management Co., Ltd.as of 31 Dec 2023277.00k0.07%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023200.00k0.05%
Dimensional Fund Advisors Ltd.as of 30 Jun 2024106.16k0.03%
SSgA Funds Management, Inc.as of 05 Sep 202497.85k0.02%
DFA Australia Ltd.as of 31 Jul 20241.83k0.00%
JPMorgan Asset Management (UK) Ltd.as of 31 Dec 20230.000.00%
Atlantis Investment Management Ltd. /Hong Kong/as of 31 Dec 20230.000.00%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.